Clinical Study Of SOX And FOLFOX4 Regimen In The Treatment Of Gastric Cancer After Surgery

Objectives By comparing the SOX project(oxaliplatin + tigeo capsule)and FOLFOX4 program(oxaliplatin + leucovorin calcium + fluorouracil)as gastric cancer postoperative adjuvant chemotherapy of disease-free survival and overall survival and adverse reaction as well as the comparison of two groups of 1 year,2 years of disease-free survival and 1 year,2 years of survival rate,understand chemotherapy regimens whether there is obvious difference in both groups,provide reference for clinical treatment.Methods Retrospective analysis of 104 cases of gastric cancer patients admitted to our hospital from March 2013 to December 2015 was divided into two groups according to the admission order.SOX group 42 cases: oxaliplatin 130mg/m~2,intravenous drip 2h,d1;Sergio:body surface area <1.25m~2: 80mg/d;1.25 1.5 m~2: 100 mg/d;It is more than 1.5m~2:120mg/d,which is taken orally twice,after the meal is 0.5h,and 14 d consecutively,and the rest is 7d,which is 1 cycle every 3 weeks.FOLFOX4 group 62 cases: oxaliplatin 85mg/m~2 intravenous drip 2h,d1;Folic acid calcium 200mg/m~2 intravenous drip 2h,d1,2;The fluorouracil 400mg/m~2 venous rapid static point d1,2,after fluorouracil 600mg/m~2,continuous intravenous drip 22 h,d1,2.Repeat every 2 weeks,4 weeks for 1 cycle.Results 1.There was no significant difference in the disease-free survival period(DFS)between the SOX group and the FOLFOX4 group,and the disease-free survival rate was 83.3%,87.1% and 35.7%,45.2% respectively,χ2=0.761,P=0.383.In terms of survival(OS),two groups have no significant difference,the SOX group total survival rate was 71.4%(30/42),FOLFOX4 group total survival rate was 54.8%(34/62),1,2 year survival rates were 90.5%,93.5% and 81.0%,83.9%,χ2 = 0.587,P = 0.444,there is no statistical significance.2.The incidence of blood system toxicity in FOLFOX4 group was higher than that in the SOX group,mainly with leukocyte and neutrophil reduction.The incidence rate was 72.6%(45/62)in FOLFOX4 group and 52.4%(22/42)in the SOX group,and the difference was statistically significant(P=0.025).Neutrophils reduced the incidence of FOLFOX4 group by 80.6%(50/62),and the SOX group 59.5%(25/42),with significant difference(P=0.008).In addition,the incidence of hair loss and peripheral neurotoxicity in FOLFOX4 group was significantly higher than that in the SOX group (P=0.000、P=0.004).There was no statistically significant difference between the two groups in gastrointestinal tract,oral mucosa,liver and renal function(P >0.05).Conclusions Patients with gastric cancer were treated with SOX or FOLFOX4 as adjuvant chemotherapy.The related adverse reactions were mainly manifested in the blood system,gastrointestinal tract,oral mucosa,hair loss,peripheral neurotoxicity,liver and kidney dysfunction,etc.FOLFOX4 group of white blood cells and neutropenia,alopecia,the incidence of peripheral nerve toxicity was significantly higher than that of the SOX group,but more to Ⅰ~ Ⅱ、Ⅲ ~ Ⅳ level low incidence of adverse reactions;Both young patients(<60 years old)and elderly patients(≥60 years old)were tolerated.